Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunfa Cheng

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Brain and Behavior|February 24, 2022
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studiesKoichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trialStewart J Tepper, Hans-Christoph Diener, Messoud Ashina, et al.
Headache|May 20, 2022
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysisMessoud Ashina, Stewart J Tepper, Jan Lewis Brandes, et al.
Cephalalgia : an International Journal of Headache|December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% responseJan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
The Journal of Headache and Pain|October 3, 2018
Early onset of efficacy with erenumab in patients with episodic and chronic migraineTodd Schwedt, Uwe Reuter, Stewart Tepper, et al.
Neurology|December 20, 2019
Vascular safety of erenumab for migraine preventionDavid Kudrow, Julio Pascual, Paul K Winner, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical TrialGeoffrey A Block, David A Bushinsky, Sunfa Cheng, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Plos One|April 22, 2025
Correction: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panelDavid E Henner, Beatrice Drambarean, Teresa M Gerbeling, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Brain and Behavior|February 24, 2022
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studiesKoichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trialStewart J Tepper, Hans-Christoph Diener, Messoud Ashina, et al.
Headache|May 20, 2022
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysisMessoud Ashina, Stewart J Tepper, Jan Lewis Brandes, et al.
Cephalalgia : an International Journal of Headache|December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% responseJan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
The Journal of Headache and Pain|October 3, 2018
Early onset of efficacy with erenumab in patients with episodic and chronic migraineTodd Schwedt, Uwe Reuter, Stewart Tepper, et al.
Neurology|December 20, 2019
Vascular safety of erenumab for migraine preventionDavid Kudrow, Julio Pascual, Paul K Winner, et al.
JAMA|January 19, 2017
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical TrialGeoffrey A Block, David A Bushinsky, Sunfa Cheng, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|January 19, 2013
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)John J V McMurray, Inder S Anand, Rafael Diaz, et al.
Plos One|April 22, 2025
Correction: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panelDavid E Henner, Beatrice Drambarean, Teresa M Gerbeling, et al.
Pageof 5